http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
金陣鶴,全外述 慶熙大學校 1996 論文集 Vol.25 No.-
Today, There has been rapid change in international trade environment due to regional economic block, the protectionism of developed countries and the intensification of global competition etc. Therefore, the international business activity of enterprises is most emphasized and the regional study is regarded very important in drafting economic policy of our government and formulating business strategy of enterprises. Especially, many socialistic countries has been adopting market economy system for their economic development, which is a very good chance to expand new foreign markets by korean enterprises. On the other hand, now, Vietnam has been continually making an amendment of its law in order to attract foreign investment for economic development. Under this situation, a poor grasp of continually amended law may cause a lot of risk. So, this study deals with some cautions to settle disputes by arbitration in investment into Vietnam.
Park, Jong Il,Han, sang seop,Jeong, Tae Cheon,Roh, Jung Koo,Kim, Hyoung Chin,Kim, Jeong Hwan,Jeon, Yeong Joong,Kim, Dal Hyun,Kim,Je Hak,Park, Kwan Ha 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.1
The antigenic potential of CFA-001, cefazolin, a cephalosporin derivative produced by an enzymatic semisynthesis, was determined in Hartley guinea pigs. A battery of tests employed consisted of active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA), and indirect hemagglutination test (IHA). The results were as follows: 1) In ASA, no signs attributable to anaphylaxis was observed in guinea pigs sensitized with CFA-001, whereas OVA-sensitized animals induced severe anaphylactic symptoms; 2) guinea pigs did not produce antibodies against CFA-001 when sensitized with or without Freund's complete adjuvant (FCA) in homologous PCA tests. Meanwhile, antibodies against ovalbumin (OVA) were clearly detected; 3) No CFA-001-specific hemagglutination was observed in the IHA using sera obtained from CFA-001-sensitized guinea pigs. These results suggest that CFA-001 has no antigenicity potential in guinea pigs.
Mun, Chin Hee,Kim, Jin-Ock,Ahn, Sung Soo,Yoon, Taejun,Kim, Su Jeong,Ko, Eunhee,Noh, Hee-Dong,Park, Yong-Beom,Jung, Hak-Jun,Kim, Tae Sung,Lee, Sang-Won,Park, Sang Gyu Elsevier 2019 Biomaterials Vol.220 No.-
<P><B>Abstract</B></P> <P>Aminoacyl-tRNA synthetase (ARS)-interacting multifunctional protein 1 (AIMP1) enhances the expression of proinflammatory cytokines. In our previous study, we have shown that serum AIMP1 in patients with SLE was significantly higher than that of healthy controls. To address whether neutralization of AIMP1 could ameliorate nephritis in lupus-prone mice, we generated atializumab, a humanized antibody against AIMP1 and investigated its therapeutic efficacy. ELISA showed that serum AIMP1 at 23 weeks old was significantly higher than that at 13 weeks old in lupus-prone mice. Therefore, lupus-prone mice were randomly assigned to 5 groups (vehicle, methylprednisolone and 0.5, 2, and 5 mg/kg atializumab). After treatment, disease severity was assessed using a variety of phenotypes, including proteinuria, histological damages, renal deposition of immune-complex. In addition, serum cytokines, anti-dsDNA and IgG subclasses were determined. T cell subsets were analyzed using a fluorescence-activated cell sorter. Atializumab significantly diminished proteinuria, improved glomerular and tubular damages and reduced the renal deposition of immune-complexes. Moreover, atializumab significantly decreased serum interferon (IFN)-γ, interleukin (IL)-17A, and IL-6, whereas it increased serum IL-10. Similarly, atializumab reduced the numbers of T<SUB>H</SUB>1, T<SUB>H</SUB>2 and T<SUB>H</SUB>17 cells in a dose-dependent manner, while atializumab enhanced the number of regulatory T (Treg) cells. Furthermore, atializumab decreased not only splenic plasma cells and serum anti-dsDNA but also pathogenic IgG subclasses for nephritis. It suppressed NF-κB activation by inhibiting IκBα degradation in a dose-dependent manner <I>in vitro</I>. Atializumab alleviated nephritis by inhibiting autoreactive T, B, and plasma cells and decreasing NF-κB-related proinflammatory cytokines in lupus-prone mice. These results suggest that treatment targeting AIMP1 could be a novel and highly immune-modulating therapeutic strategy in lupus nephritis.</P>